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Abstract In human bronchial epithelial (16HBE14o−)
cells, CB1 and CB2 cannabinoid receptors are present, and
their activation by the endocannabinoid virodhamine and
the synthetic non-selective receptor agonist CP55,940
inhibits adenylyl cyclase and cellular interleukin-8 release.
Here, we analyzed changes in intracellular calcium ([Ca2+]i)
evoked by Δ9-tetrahydrocannabinol (Δ9-THC), CP55,940,
and virodhamine in 16HBE14o− cells. Δ9-THC induced
[Ca2+]i increase and a large transient [Ca
2+]i mobilization,
the latter probably reflecting store-depletion-driven capaci-
tative Ca2+ entry (CCE). In contrast, CP55,940 induced a
rather moderate Ca2+ influx and a sustained [Ca2+]i
mobilization. CP55,940-induced Ca2+ influx was inhibited
by Ni2+, indicating CCE, possibly mediated by transient
receptor potential channel TRPC1, the mRNA of which is
expressed in 16HBE14o− cells. CP55,940-induced calcium
alterations were mimicked by virodhamine concentrations
below 30μM. Interestingly, higher virodhamine induced an
additional Ca2+ entry, insensitive to Ni2+, but sensitive to
the TRPV1 antagonist capsazepine, the TRPV1-TRPV4
inhibitor ruthenium red, and the non-CCE (NCCE) inhib-
itors La3+ and Gd3+. Such pharmacological profile is
supported by the presence of TRPV1, TRPV4, and TRPC6
mRNAs as well as TRPV1 and TRPC6 proteins in
16HBE14o− cells. Cannabinoid receptor antagonists in-
creased virodhamine-induced Ca2+ entry. Virodhamine also
enhanced arachidonic acid release, which was insensitive to
cannabinoid receptor antagonism, but sensitive to the
phospholipase A2 inhibitor quinacrine, and to capsazepine.
Arachidonic acid induced [Ca2+]i increase similar to
virodhamine. Collectively, these observations suggest
that [Ca2+]i alterations induced by Δ
9-THC, CP55,940
and by low concentrations of virodhamine involve
mobilization and subsequent CCE mechanisms, whereas
such responses by high virodhamine concentrations
involve NCCE pathways.
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Introduction
In the last decades, two cannabinoid receptor (CBR) subtypes
have been identified, cloned, expressed, and functionally
investigated (Matsuda et al. 1990; Munro et al. 1993). The
CB1R has primarily been observed in central and peripheral
nervous structures (Tsou et al. 1998), whereas the CB2R is
predominantly found in immune cells (Berdyshev 2000;
Galiegue et al. 1995; Munro et al. 1993; Schatz et al. 1997).
Interestingly, (endo)cannabinoid-mediated effects indepen-
dent of the CB1R and the CB2R have been described (Oz
2006; Pertwee 2005). Such (endo)cannabinoid responses
may involve orphan receptors GPR119 and GPR55; in
addition, transient receptor potential (TRP) channels are also
a matter of debate (Brown 2007; Rao and Kaminski 2006b;
Clapham et al. 2005).
Naunyn-Schmied Arch Pharmacol (2009) 380:67–77
DOI 10.1007/s00210-009-0406-z
Effimia Gkoumassi and Bart G. J. Dekkers contributed equally to this
work.
E. Gkoumassi (*) : B. G. J. Dekkers (*) :M. J. Dröge :
C. R. S. Elzinga : R. E. Hasenbosch :H. Meurs :
S. A. Nelemans :M. Schmidt : J. Zaagsma
Department of Molecular Pharmacology,
University Centre for Pharmacy, University of Groningen,
A. Deusinglaan 1,
9713 AV Groningen, The Netherlands
e-mail: e.gkoumassi@gmail.com
e-mail: b.g.j.dekkers@rug.nl
Both the CB1R and the CB2R belong to the G-protein-
coupled receptor superfamily and primarily couple to
pertussis toxin-sensitive and adenylyl cyclase-inhibitory
Gi/o-proteins (Childers and Deadwyler 1996; Felder et al.
1995; Hofmann et al. 2000; Gkoumassi et al. 2007).
Enhancement of cAMP production through linkage to Gs-
proteins, however, has been reported as well (Bonhaus et al.
1998; Gkoumassi et al. 2007; Glass and Felder 1997).
Recently, we have shown that both CBR subtypes are
present in human bronchial epithelial (16HBE14o−) cells
and are functionally coupled to adenylyl cyclase. We found
that, in response to the endocannabinoid virodhamine and
the synthetic cannabinoid CP55,940, the CB2R signaling
pathway is predominant and inhibits adenylyl cyclase and
the cellular release of interleukin-8. Following pretreatment
with pertussis toxin, increased accumulation of cAMP
became apparent, however, which was mediated by CB1R.
Interestingly, the synthetic cannabinoid CP55,940 evoked
such 16HBE14o− cell responses less efficiently compared
to the endocannabinoid virodhamine (Gkoumassi et al.
2007). Indeed, CP55,940 acts as a non-selective receptor
agonist (Burkey et al. 1997; Thomas et al. 2007), whereas
virodhamine acts as a partial agonist on the CB1R and as a
full agonist on the CB2R (Porter et al. 2002).
Next to the modulation of adenylyl cyclase, (endo)
cannabinoid-induced changes in intracellular calcium
([Ca2+]i) have been investigated in various cell types. We
reported that the phytocannabinoid Δ9-tetrahydrocannabinol
(Δ9-THC) and the synthetic cannabinoid CP55,940 induced
Ca2+ influx and [Ca2+]i mobilization in DDT1 MF-2 smooth
muscle cells, processes being dependent on the CB1R
(Filipeanu et al. 1997) and on the release of arachidonic
acid (Begg et al. 2001; Demuth et al. 2005). Recent reports
indicated that Δ9-THC, but not CP55,940, induced Ca2+
alterations in resting T cells independent of CB1R and CB2R
(Rao et al. 2004; Rao and Kaminski 2006a), but dependent
on Ca2+ influx through the TRP channel TRPC1 (Rao and
Kaminski 2006b). Interestingly, the endocannabinoid anan-
damide has been shown to activate the TRP family member
TRPV1 (Clapham et al. 2005).
In bronchial epithelial cells, changes in intracellular
calcium are importantly involved in the regulation of mucus
secretion, cytokine production, surfactant secretion, and
ciliary beat frequency (Conway et al. 2003; Sakamoto et al.
2007; Haller et al. 1998; Lansley et al. 1992). Exposure of
epithelial cells to cannabinoids may represent a result of
marijuana smoke (Δ9-THC) or endogenously released
cannabinoids like virodhamine and anandamide (Porter et
al. 2002). However, the effects of (endo)cannabinoids on
intracellular calcium alterations in bronchial epithelial cells
have not been described yet. Therefore, we aimed in the
current study to identify and to characterize alterations in
intracellular calcium evoked by (endo)cannabinoids in
human bronchial epithelial (16HBE14o−) cells. As it has
been reported that the newly identified (endo)cannabinoid
virodhamine is present in two to nine times higher
concentrations in peripheral tissues than the classical
(endo)cannabinoid anandamide (Porter et al. 2002), we
studied the effect of virodhamine in comparison to Δ9-
THC and CP55,940. We demonstrated that Δ9-THC,
CP55,940, and low concentrations of virodhamine in-
duced [Ca2+]i increases in 16HBE14o
− cells involving
mobilization and subsequent capacitive calcium entry
(CCE) mechanisms, whereas high virodhamine concen-




All chemicals were of analytical grade and obtained
from Sigma (Zwijndrecht, The Netherlands), unless
stated otherwise. Virodhamine [O-(2-aminoethyl)-5Z,8Z,




methyl-3-pyrazole-carboxamide) were obtained from Tocris-
Cookson (Avonmouth, UK). Δ9-Tetrahydrocannabinol
(Δ9-THC) was a gift from Dr. H. W. Frijlink (University of
Groningen). SR144528 [N-[(1S)-endo-1,3,3-trimethyl bicy-
clo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-
methylbenzyl)-pyrazole-3-carboxamide] was a gift from Sanofi
(Montpellier, France). CP55,940 (5-(1,1-dimethylheptyl)-2-
[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol) was
obtained from Sigma (Zwijndrecht, The Netherlands). Stock
solutions of Δ9-THC, virodhamine and arachidonic acid,
were prepared in ethanol, shielded from light, and stored at
−20°C. SR141716A and SR144528 were dissolved in dimeth-
yl sulfoxide (DMSO) and stored at room temperature.
Lanthanum (III) chloride, gadolinium (III) chloride, and nickel
(II) chloride solutions were prepared freshly in distilled water.
Stock solution of quinacrine [6-chloro-9-(4-diethylamino-1-
methylbutylamino)-2-methoxyacridine dihydrochloride]
was prepared in DMSO and stored at 4°C. Thapsigargin was
dissolved in DMSO and stored at −20°C. Capsazepine was
dissolved in ethanol and stored at −20°C. Ruthenium red
was dissolved in distilled water and stored at room
temperature. The antibody directed to TRPC6 was a gift
from Dr. Alexander Dietrich (Hofmann et al. 2000;
Dietrich et al. 2003), and the antibody directed to TRPV1
was from Biomol (Exeter, UK).
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Cell culture
The immortal human bronchial epithelial cell line 16HBE14o−
(Cozens et al. 1994) was a kind gift from Dr. D. C. Gruenert
(University of Vermont, Burlington VT, USA). Cells were
grown at 37°C in minimum essential medium (MEM),
supplemented with 10% fetal bovine serum, penicillin
(50µg/ml), streptomycin (50µg/ml), and L-glutamine
(2 mM) in fibronectin/collagen coated flasks to near
confluency in an atmosphere of 5% CO2/95% O2. For
arachidonic acid release studies, cells were plated into
9.6 cm2 six well plates. All culture media and supplements
were obtained from Life Technologies (Breda, The
Netherlands). Cell culture dishes were from Costar
(Badhoevedorp, The Netherlands), and flasks were from
Greiner (Alphen a/d Rijn, The Netherlands).
Intracellular Ca2+ measurements
Intracellular [Ca2+] was measured using Fura-2 fluorometry
as reported previously (Demuth et al. 2005). Briefly, cells
were trypsinized and loaded in suspension with 3μM Fura-
2 acetoxymethylester at 37°C for 45 min in the dark.
Fluorescence was measured at 37°C. When used, receptor
antagonists (SR141716A and SR144528 1µM) and channel
inhibitors (capsazepine 10µM, ruthenium red 20µM, Gd3+
1µM, La3+ 10µM, Ni2+ 1 mM) were added 10 min prior to
the agonist.
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy minikit (Qiagen,
Venlo, The Netherlands) according to the manufacturer's
instructions. RNA samples were purified with a RQ1
RNAse-free DNAse to remove genomic DNA contamina-
tions. Subsequently, RNA (1μg) was transcribed into
cDNA using the Promega RT system kit. PCR reactions
were performed using the Promega RT-PCR Core system
kit (Leiden, The Netherlands), according to the manufac-
turer's instructions, using a Mastercycler Gradient (Eppen-
dorf, Hamburg, Germany). For the detection TRP channels
the following primer pairs were obtained from Invitrogen
(Leek, The Netherlands): TRPC1 (forward): 5′-GTG CGG
GAG GTG AAG GAG GAG AAT-3′; TRPC1 (reverse): 5′-
CTG CAT GGG GCT TGG GTA GAG ATA-3′; TRPC6
(forward): 5′-ATG ATATGG GCT GAATGT AAA GA-3′;
TRPC6 (reverse): 5′-TCA AAG TAG GAA AAC CAG
AG-3′; TRPV1 (forward): 5′-CTA ACT CCA GGC CAC
CTC CA-3′; TRPV1 (reverse): 5′-GCC ATG TTG CGT
CTC TCG AT-3′; TRPV4 (forward): 5′-TAC TAT CGA
GGT CAG ACA GC-3′; TRPV4 (reverse): 5′-CCG CAG
CAG TTC ATT GAT GG-3′. With these primers, the
amplified gene fragments were 463, 752, 562, and 678 bp,
respectively. PCR reactions that comprised of a denaturing
step at 94°C for 5 min was followed by amplification for
30 cycles at 94°C, 1 min; annealing temperature, 1 min; 72°C,
1 min; with final extension at 72°C for 10 min. The
annealing temperature used for TRPC1 was 52°C, 60°C
for TRPC6, and 58°C for TRPV1 and TRPV4. The
amplified product (2µl) was separated on a 2% agarose
gel, and the DNA was visualized by ethidium bromide. A
100 bp ladder (MBI Fermentas, St. Leon-Rot, Germany)
was used as DNA marker. Restriction analysis was
performed with EcoRI for TRPC1 (expected fragments
335 and 128), with HindIII for TRPC6 (expected fragments
342 and 410), with PstI for TRPV1 (expected fragments 328
and 234), and HincII for TRPV4 (expected fragments 477
and 201; Sigma, Zwijndrecht, The Netherlands) for 2 h at
37°C according to the manufacturer's protocol.
Immunoblot analysis
Western blot analysis was performed as described before
(Gkoumassi et al. 2007; Hassock et al. 2002; Hofmann et
al. 2000). Briefly, cell lysate (corresponding to 10–15µg
protein per lane) was separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, using 10%
gel at 100 V. Proteins in the gel were transferred onto
nitrocellulose membranes, which were subsequently
blocked with blocking buffer (Tris–HCl 50 mM, NaCl
150 mM, Tween-20 0.1%, dried milk powder 5%) for
90 min. Membranes were incubated overnight at 4°C
using 1:1,000 dilution of rabbit polyclonal antiserum
raised against the C-terminal peptide VGHNKQPSIRS-
SEDFHLNSFNNPP (amino acids 829–852 of hTRPC6);
the rabbit polyclonal antiserum against the TRPV1 was
used at a dilution of 1:200. After three washes of 10 min
each, membranes were incubated with horseradish
peroxidase-labeled secondary antibodies (1:3,000 in
blocking buffer) for 90 min at room temperature,
followed by another three washes. Antibodies were
visualized by enhanced chemiluminescence.
Arachidonic acid release measurements
[3H]Arachidonic acid release was measured as described
previously (Demuth et al. 2005; Van der Zee et al. 1995). In
short, cells were grown to confluency in 9.6 cm2 six well
plates and labeled with 0.25µCi of [3H]arachidonic acid
(specific activity, 60–100 Ci (2.22–3.70 TBq)/mmol) in
serum-free MEM (1 ml), for 3 h at 37°C. Cells were
washed once in extracellular salt solution (ECS) containing
(mM): NaCl, 125; KCl, 6; MgCl2, 2.5; NaH2PO4, 1.2;
Hepes, 20; glucose, 11; sucrose, 67; CaCl2, 1.2; pH7.4,
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twice with ECS containing 1% BSA (fatty acid-free) and
once again with ECS to eliminate unincorporated radioac-
tivity; subsequently, cells were allowed to equilibrate for
15 min, in the absence or presence of the inhibitors. Cells
were stimulated with the agonist for 5 min, and the
incubation was stopped by removing the ECS. [3H]
Arachidonic acid release into the ECS was quantified using
liquid-scintillation counting.
Data analysis
Values are expressed as means±standard error of the mean
(SEM). Comparison of pairs of treatments was made using
Student's t test. P < 0.05 was considered significant. All
curves were fitted using a logistic fit four-parameter model
(SigmaPlot 10, SYSTAT Software, Chicago IL, USA).
Results
To assess the effects of (endo)cannabinoids on alterations in
intracellular calcium ([Ca2+]i) in 16HBE14o
− cells, we
incubated the cells with different concentrations of Δ9-
THC, CP55,940, and virodhamine. The phytocannabinoid
Δ9-THC evoked a large dose-dependent [Ca2+]i increase
(Fig. 1b and c), consisting of a relatively fast peak
(transient) and a sustained plateau phase (Fig. 1a). In the
absence of extracellular Ca2+, a depressed transient
response remained, whereas the sustained plateau phase
was abrogated (Fig. 1b and c). Analysis of the
concentration-effect curves indicated pEC50 values of
4.57 ± 0.05 (n = 6) and of 4.56 ± 0.08 (n = 5) for Δ9-
THC peak responses in the presence and absence of
extracellular Ca2+, respectively; maximal Δ[Ca2+]i follow-
ing Δ9-THC stimulation were 472 ± 36 and 176 ± 29 nM
Ca2+, in the presence and absence of extracellular Ca2+,
respectively. For the plateau phase a pEC50 value of
4.59 ± 0.73 and a maximal Δ[Ca2+]i of 199 ± 28 nM were
obtained in the presence of extracellular Ca2+, which
changed into 5.00 ± 0.23 and a maximal [Ca2+]i of
21 ± 8 nM under Ca2+-free conditions. The similarities
between the pEC50 values suggest that [Ca
2+]i mobilization
and influx following Δ9-THC administration share a
common origin.
The synthetic cannabinoid CP55,940 induced a moderate
and rather sustained dose-dependent [Ca2+]i increase
(Fig. 2). The maximal Δ[Ca2+]i, in the presence of
extracellular Ca2+ was 70.3 ± 2.5 nM Ca2+ with a pEC50
value of 5.32 ± 0.03 for this agonist. Of note, higher
concentrations of CP55,940 did not further increase [Ca2+]i
(data not shown). In the absence of extracellular Ca2+, the
value for the maximal Δ[Ca2+]i was 27.6 ± 0.6 nM with a
pEC50 value of 5.76 ± 0.18 (Fig. 2b), indicating that
CP55,940-induced [Ca2+]i increase involves continuous
[Ca2+]i mobilization and [Ca
2+]i influx.
To gain insight into the impact of capacitative Ca2+ entry
(CCE) in cannabinoid-driven calcium alterations in
16HBE14o− cells, we first estimated CCE following





















































Fig. 1 Changes in [Ca2+]i evoked by Δ
9-tetrahydrocannabinol (Δ9-
THC) in 16HBE14o− cells. a Representative traces obtained in the
presence and absence of extracellular Ca2+ induced by 100µM Δ9-
THC administered at t = 60 s. b Concentration-response curves of the
maximal Δ[Ca2+]i for peak values induced by Δ
9-THC in the
presence (closed circles) and absence (open circles) of extracellular
Ca2+. c Concentration-response curves of the maximal Δ[Ca2+]i for
the plateau values induced by Δ9-THC in the presence (closed circles)
or absence (open circles) of extracellular Ca2+. Data in b and c are
presented as means±SEM of five to eight experiments
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intracellular store depletion (Fig. 3). After emptying Ca2+
stores with thapsigargin under Ca2+-free conditions,
reintroduction of extracellular Ca2+ induced a large CCE-
dependent Ca2+ influx, which could be abolished concen-
tration dependently by the CCE inhibitor Ni2+ (Sweeney et
al. 2002a), but not by the NCCE inhibitors Gd3+ or La3+
(Clapham et al. 2005; Demuth et al. 2005; Fig 3a and b).
The CCE-dependent Ca2+ entry was inhibited by Ni2+ ions
with a pIC50 of 2.99 ± 0.25 (Fig. 3c). Importantly, the
CP55,940-induced Ca2+ influx was also completely
blocked by the CCE inhibitor Ni2+, strongly pointing to
the involvement of CCE in CP55,940 driven Ca2+ influx
(Fig. 4a). Previous studies have implicated that TRPC1 is
involved in CCE (Clapham et al. 2005; Sweeney et al.
2002b) and that cannabinoids induce Ca2+ influx in part via
these channels (Rao and Kaminski 2006b). Indeed, PCR
analysis revealed that mRNA for the TRP channel TRPC1
was expressed by 16HBE14o− cells (Fig. 4b), which is in
agreement with previous findings in primary HBE cells
(Corteling et al. 2004).




























Fig. 2 Changes in [Ca2+]i evoked by CP55,940 in 16HBE14o
− cells.
a Representative traces obtained in the presence and absence of
extracellular Ca2+ induced by 100µM CP55,940 administered at
t = 60 s. b Concentration-response curves of the maximal Δ[Ca2+]i
values induced by CP55,940 in the presence (closed circles) and
absence (open circles) of extracellular Ca2+. Data in b are presented as
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Fig. 3 Effects of Ni2+, La3+, and Gd3+ on thapsigargin-evoked
capacitative Ca2+ entry (CCE) in 16HBE14o− cells. Internal Ca2+
stores were depleted with 1µM thapsigargin in Ca2+-deficient
medium. Reintroduction of extracellular Ca2+ (1 mM) increased
intracellular [Ca2+] reflecting activation of CCE. a Sample trace of
the effect of cumulatively administered concentrations of Gd3+ (0.01,
0.1, 1, 10, and 100µM) on CCE-dependent increases in [Ca2+]i
starting at *a, followed by addition of Ni2+ (*b 1 mM; *c 3 mM; *d
10 mM). b Sample trace of the effect of La3+. Cumulative
concentrations were 0.01, 0.1, 1, 10, and 100µM starting at *a,
followed by addition of Ni2+ (*b 1 mM; *c 3 mM; *d 10 mM). In
contrast to Ni2+, no effects on CCE-dependent increases in [Ca2+]i
were observed with Gd3+ or La3+ (n = 3). c Concentration-response
curve of the effect induced by Ni2+ alone. Data in c are presented as
means±SEM of three experiments
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Virodhamine (O-arachidonoyl ethanolamine), a novel
endocannabinoid structurally closely related to anandamide,
also induced [Ca2+]i increase in a concentration-dependent
fashion (Fig. 5). Interestingly, however, we observed two
distinctive patterns, consisting of a slow and moderate
[Ca2+]i increase at virodhamine concentrations below 30µM
and a large, fast, and almost linear [Ca2+]i increase at high
virodhamine (30μM) and higher (not shown) concentra-
tions. The vehicle ethanol induced only a negligible [Ca2+]i
increase (data not shown). Under Ca2+-free conditions,
higher concentrations of virodhamine did not further
enhance [Ca2+]i increase, indicating that this cellular
response was fully dependent on influx of extracellular
Ca2+ (Fig. 5b and c). Under Ca2+-free conditions, a plateau
in the maximal Δ[Ca2+]i was reached with a maximal
Δ[Ca2+]i of 50.0 ± 10.1 nM and a pEC50 value of
5.10 ± 0.19 (Fig. 5c). Surprisingly, the CB1R antagonist
SR141716A further enhanced the virodhamine (30µM)-
induced [Ca2+]i increase, whereas the NCCE-inhibitor Gd
3+
and the TRPV1-TRPV4 inhibitor ruthenium red strongly
reduced the large Ca2+ influx component (Fig. 5b). To
further assess the potential role of CBR subtypes and Ca2+
channels, we quantified the virodhamine-induced calcium
alterations (Fig. 6). Both the CB1R antagonist SR141716A
and the CB2R antagonist SR144528 augmented [Ca
2+]i
increase in response to 10 and 30μM virodhamine,
suggesting an inhibitory effect of the CBRs on
virodhamine-induced Ca2+ influx. The CBR antagonists
did not alter the control level of [Ca2+]i (data not shown).
As (endo)cannabinoids have been implicated in the
activation of the vanilloid receptor/Ca2+ channel TRPV1
(Clapham et al. 2005), we studied the effect of the TRPV1
antagonist capsazepine (CPZ) on the virodhamine-induced
Ca2+ influx as well. At low (10μM) virodhamine concen-
trations, CPZ did not alter the virodhamine-induced [Ca2+]i
increase (Fig. 6a). At high (30μM) virodhamine concen-
trations, however, the virodhamine-induced [Ca2+]i increase
was sensitive to CPZ (Fig. 6b), implying the involvement
of TRPV1 channels in this response. The classical
vanilloid-TRPV receptor agonist capsaicin (1–100 µM) by
itself did not affect intracellular calcium concentrations
(data not shown), and pretreatment with capsaicin did not
significantly increase virodhamine-induced calcium alter-
ations (P = 0.14; Fig 6a). Interestingly, the TRPV1–TRPV4
inhibitor ruthenium red was able to reduce virodhamine (30
µM)-induced [Ca2+]i increase as well (Fig. 6b). As we
observed the presence of TRPV1 and TRPV4 mRNAs and
TRPV1 protein in 16HBE14o− cells (Fig. 6c and d) and a
previous study has reported the presence of the TRPV4
protein in differentiated primary HBE cells (Sidhaye et al.
2008), a potential role for such Ca2+ channels in
virodhamine-induced Ca2+ influx should be envisaged as
well. Almost complete inhibition of virodhamine-induced
Ca2+ influx was achieved by the NCCE inhibitors Gd3+ and
La3+ used at low concentrations of 1 and 10µM, respec-
tively (Fig. 6b). In contrast, the CCE inhibitor Ni2+ did not
inhibit virodhamine-induced Ca2+ influx, even at a concen-
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Fig. 4 Effect of CCE blockade on CP55,940-induced [Ca2+]i
increase. a CP55,940 (10µM)-induced changes in [Ca2+]i in the
presence and absence of extracellular Ca2+ and in the presence of Ni2+
(10 mM, added after reaching the sustained phase in the presence of
extracellular Ca2+). Data in a are presented as means±SEM of four
experiments. *P < 0.05 vs. control. N.S. not significantly different.
b mRNA expression of TRPC1 in 16HBE14o− cells. Total RNA was
reverse-transcribed into cDNA, and specific fragments were amplified
by PCR, separated on 2% agarose gel, and visualized with ethidium
bromide. Restriction analysis, performed with EcoRI, is presented in
the right lane
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clearly point to a role NCCE mechanisms in the calcium
response induced by high virodhamine concentrations.
Currently, TRPC6 channels are the only channels known
to be sensitive to low concentrations of Gd3+ and La3+
(Clapham et al. 2005). Indeed, in agreement with findings
in primary HBE cells (Corteling et al. 2004), we detected
both mRNA and protein of TRPC6 in 16HBE14o− cells.
Next to the 100 kDa immunoreactive positive TRPC6 band,
an additional band of 73 kDa was visible, similar to the
band reported before in HEK293 cells (Dietrich et al.
2003).
Since arachidonic acid has been shown to be an important
mediator in NCCE-dependent Ca2+ entry (Demuth et al.
2005;Van der Zee et al. 1995; Shuttleworth and Thompson
1999), we also investigated the release of this lipid
mediator by 16HBE14o− cells upon stimulation with
virodhamine. A concentration-dependent release of arach-
idonic acid was observed (pEC50 = 5.19 ± 0.16), which did
not increase further at concentrations above 10μM,
indicating that virodhamine-induced arachidonic acid re-
lease may be involved in NCCE (Fig. 7a). This release was
sensitive to the phospholipase A2 inhibitor quinacrine, but
insensitive to CBR antagonists (Fig. 7b). Virodhamine-
induced arachidonic acid release was, however, sensitive to
capsazepine treatment, and a trend towards a decrease in
arachidonic acid release was observed for ruthenium red,
indicating that TRPV1 channels may be involved in these
responses. Finally, to assess whether arachidonic acid could
be involved in the activation of TRPV1 by virodhamine, we
investigated the effects of arachidonic acid on [Ca2+]i
increase. Concentrations of arachidonic acid between 1
and 30μM induced a concentration-dependent [Ca2+]i
increase, with a pEC50 = 5.17 ± 0.63 and a maximal
Δ[Ca2+]i of 97.3 ± 7.5 nM (Fig. 8a and b). Higher
concentrations of arachidonic acid (≥100μM) induced a
large, fast, and almost linear increase at high concentrations
(Fig 8a), very similar to the effects observed for the high
virodhamine concentrations.
Discussion
In the present study, we report for the first time that the
structurally distinct (endo)cannabinoids Δ9-THC,
CP55,940, and virodhamine induce intracellular [Ca2+]i
increase driven by different mechanisms in human bron-
chial epithelial 16HBE14o− cells. All three compounds
induce an [Ca2+]i increase by Ca
2+ entry from the
extracellular space, but for Δ9-THC, this Ca2+ influx is
subsequent to a large transient [Ca2+]i mobilization and
may therefore reflect a store-depletion-driven CCE mech-
anism. Indeed, we reported in previous studies in DDT1
MF-2 smooth muscle cells that the Δ9-THC-induced Ca2+
release from thapsigargin-sensitive intracellular stores in-
volved the CB1R and subsequent CCE mechanisms
(Filipeanu et al. 1997). Interestingly, Δ9-THC induced an
additional Ca2+ influx in these cells independent of CB1R
and CB2R. Recently, a robust Δ
9-THC-induced Ca2+ influx
was reported in resting T cells, also independent of CB1R
and CB2R (Rao and Kaminski 2006a) and at least partly
mediated by TRPC1 channels (Rao and Kaminski 2006b).
While thapsigargin-sensitive CCE mechanisms are opera-
tive in 16HBE14o− cells and cellular gene transcription of
TRPC1 channels was present and the involvement of


























































Fig. 5 Virodhamine-induced changes in [Ca2+]i. a Representative
traces showing the effect of virodhamine 10, 20, and 30µM. b Effect
of 30µM virodhamine (control) on [Ca2+]i in the absence and presence
of 1µM SR141716A (SR1), 20µM ruthenium red (RR), and 1µM
Gd3+ (Gd3+) and in the absence of extracellular Ca2+ (Ca2+-free). The
different inhibitors were added 10 min prior to virodhamine
application at t = 60 s. c Concentration-response curves of the
maximal sustained increases of [Ca2+]i induced by virodhamine in the
presence (closed circles) and absence (open circles) of extracellular
Ca2+. Data in c are presented as means±SEM of four experiments
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TRPC1 channels in CCE mechanisms being well estab-
lished (Clapham et al. 2005; Sweeney et al. 2002a), it is
reasonable to assume that subsequent to Ca2+ release from
intracellular, Δ9-THC-induced Ca2+ entry may be gated
through TRPC1 channels in 16HBE14o− cells indeed.
The synthetic non-selective CBR agonist CP55,940
induced only a modest and a sustained [Ca2+]i mobilization.
We reported earlier that CP55,940 is also less efficacious
compared to the endocannabinoid virodhamine in inhibiting
cAMP accumulation and release of interleukin-8 from
16HBE14o− cells (Gkoumassi et al. 2007). The Ca2+ influx
induced by CP55,940 was inhibited by Ni2+, indicating the
involvement of a CCE mechanism, possibly mediated by
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Fig. 6 Quantification of the effects of various inhibitors on
virodhamine-induced changes in [Ca2+]i and detection of TRP
channels. a Maximal sustained increases in intracellular [Ca2+]
induced by 10µM virodhamine in the absence or presence of
SR141716A (1µM, SR1), SR144528 (1µM, SR2), capsaicin (10μM,
CPS), or capsazepine (10µM, CPZ). The different antagonists were
added 10 min prior to virodhamine application at t = 60 s. Data in a
are presented as means±SEM of four to seven experiments. b Ca2+-
influx rate induced by 30µM virodhamine in the absence or presence
of SR141716A, SR144528, capsazepine, ruthenium red (20µM, RR),
Gd3+ (1µM), La3+ (10µM), or Ni2+ (1 mM). Ca2+-influx rate
represents the maximal slope and is expressed as percent of the
control rate (30μM virodhamine). Data in b are presented as means±
SEM of eight experiments. *P < 0.05 vs. control. c mRNA expression
of TRPC6, TRPV1, and TRPV4 in 16HBE14o− cells. Total RNA was
reverse-transcribed into cDNA, and specific fragments were amplified
by PCR, separated on 2% agarose gel, and visualized with ethidium
bromide. Restriction analysis, performed with HindIII (TRPC6), PstI
(TRPV1), and HincII (TRPV4) are presented in the right lanes. d
Western analysis of the TRPC6 channel in 16HBE14o cells compared
to HEK293 cells used as positive control
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CP55,940 induced [Ca2+]i increase independent of CB1R
and predominantly by NCCE mechanisms in DDT1 MF-2
smooth muscle cells (Demuth et al. 2005), while in renal
tubular epithelial cells, CP55,940 increased [Ca2+]i by Ca
2+
entry following Ca2+ release from thapsigargin-sensitive
pools in a CBR-independent manner (Chou et al. 2001).
Collectively, these studies indicate that mechanisms distinct
from those in other cell types are operative in CP55,940-
induced [Ca2+]i increase in 16HBE14o
− cells.
Remarkably, the (endo)cannabinoid virodhamine induced
Ca2+ increase at concentrations which were 150 times
higher than we described previously for CBR-mediated
inhibition of cAMP accumulation and interleukin-8 release
from 16HBE14o− cells (Gkoumassi et al. 2007). This
observation suggests Ca2+ entry via CBR-independent
channel activation. In support of this, changes in [Ca2+]i
evoked by both low and high concentrations of virodh-
amine were increased rather than decreased in the presence
of both CB1R and CB2R antagonists, which would suggest
inhibitory effects of CBRs on [Ca2+]i alterations under
these conditions or even aspecific actions of the CBR
antagonists on cation channels (Rao et al. 2004; Rao and
Kaminski 2006a; White and Hiley 1998).
Virodhamine-induced arachidonic acid release and Ca2+
entry showed the same concentration-dependence, suggest-
ing that such cellular responses are driven by the same
NCCE mechanisms. Receptor-independent effects by
(endo)cannabinoids may be dependent on their lipophilic
nature (Oz 2006). Such processes, however, do not exclude
potential physiologically important effects with regard to
the activation of TRP channels, as concentrations of
arachidonic acid-derivatives may reach concentrations up
to 5 mM in for example human platelets, and concen-
trations as used in our current study are physiologically not
uncommon (Brash 2001; Oz 2006). Recent studies even
indicated that higher concentrations of virodhamine are
necessary for attaining the full agonist effect (Porter et al.
2002; Steffens et al. 2005; Ho and Hiley 2004).































Fig. 8 Changes in [Ca2+]i evoked by arachidonic acid in 16HBE14o
−
cells. a Representative traces obtained with different concentrations
(1–100μM) of arachidonic acid administered at t = 60 s.
b Concentration-response curves of the maximal Δ[Ca2+]i values
induced by arachidonic acid. Data in b are presented as means±SEM
of four experiments
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Fig. 7 Effects of virodhamine on arachidonic acid release.
a Concentration-response curve of virodhamine-induced arachidonic
acid release. Data in a are presented as means±SEM of eight to 12
experiments. b Effect of SR141716A (1µM, SR1), SR144528 (1µM,
SR2), quinacrine (0.1 mM, Quin), ruthenium red (20µM, RR), and
capsazepine (10µM, CPZ) on the arachidonic acid release induced
by 30µM virodhamine. *P < 0.05 vs. control (virodhamine). Data in
b are presented as means±SEM of eight experiments
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Physiological functions driven by TRPV1 and TRPV4,
including detection of heat, H+ ions, and extracellular
osmolarity (Clapham et al. 2005) may play an important
role in [Ca2+]i regulation in bronchial epithelial cells and
may be influenced by endocannabinoids (Jia and Lee
2007). Indeed, [Ca2+]i changes may affect the regulation
of mucus secretion, cytokine production, surfactant secre-
tion, and ciliary beat frequency of epithelial cells (Conway
et al. 2003; Sakamoto et al. 2007; Haller et al. 1998;
Lansley et al. 1992). Ca2+ entry induced by high virodh-
amine concentrations in 16HBE14o− cells was inhibited by
the TRPV1-TRPV4 inhibitors capsazepine and ruthenium
red. Presence of TRPV1 and TRPV4 mRNAs and protein
(TRPV1, present study; TRPV4 (Sidhaye et al. 2008))
suggest their possible involvement in the observed
responses for virodhamine. Surprisingly, the TRPV1 ago-
nist capsaicin did not affect [Ca2+]i or virodhamine-induced
changes in [Ca2+]i. These findings might be explained by
the existence of different splice variants of the TRPV1
channel, which could not be detected by our PCR primers.
Of these splice variants, TRPV1b has been shown to be
activated by heat but not by capsaicin or protons (Lu et al.
2005), indicating that this variant may be involved in the
observed effects. It is also feasible to assume that the
signaling properties from capsaicin differ from that of
virodhamine. In addition to TRPV1 and TRPV4, TRPC6 is
also likely to be involved in this Ca2+ entry process since
this channel mediates NCCE (Grant et al. 2007) and is
highly sensitive to low concentrations of La3+ and Gd3+
(Clapham et al. 2005), properties fitting well with our
results. Accordingly, both mRNA and protein for TRPC6
were expressed in 16HBE14o− cells.
Structural differences between Δ9-THC, CP55,940,
and virodhamine may be important for the distinct effects
on [Ca2+]i increase in 16HBE14o
− cells. CP55,940 shares
much structural similarity with Δ9-THC, whereas virodh-
amine, which is an ester of arachidonic acid and
ethanolamine, has much more similarity to arachidonic
acid. Indeed, arachidonic acid-induced [Ca2+]i changes
were very similar to the effects induced by virodhamine.
These effects and the effects seen with capsazepine and
ruthenium red on virodhamine-induced Ca2+ influx and
arachidonic acid release indicate that virodhamine, direct-
ly or indirectly, activates TRPV1 and TRPV4 in an
arachidonic acid-dependent fashion.
In conclusion, we have shown that the (endo)cannabinoids
Δ9-tetrahydrocannabinol, CP55,940, and virodhamine use
different mechanisms of action to elevate [Ca2+]i in
16HBE14o− cells. Δ9-THC, CP55,940, and low concen-
trations of virodhamine increase [Ca2+]i through mobilization
and subsequent CCE mechanisms, whereas higher concen-
trations of virodhamine induce [Ca2+]i increases involving
non-CB1R, non-CB2R-mediated NCCE pathways.
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